Clinical trial
Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
NCT01701999 is registered in ClinicalTrials.gov with California Department of Public Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection
- Lead sponsor
- California Department of Public Health
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 2013
- Completion date
- October 31, 2015
- Enrollment
- 45 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.